Exelixis Director David Johnson Buys 19,133 Options—Insider Bet on Future Growth Amid Executive Sell‑Offs

Insider Activity at Exelixis: A Closer Look at David Johnson’s New Option Grant

On May 27, 2026, Exelixis Inc. disclosed that owner David Johnson, a non‑executive director, acquired 19,133 immediately exercisable options under the 2017 Equity Incentive Plan. Although the transaction involves no cash outlay—options were granted at no cost—the move signals confidence in the company’s near‑term prospects. The option grant is tied to a first‑anniversary vesting schedule, suggesting Johnson’s intent to hold a long‑term stake, while the accompanying footnotes indicate that the shares will ultimately be directed to the Caligan Partners Master Fund, a professional investment vehicle.

What Does This Mean for Investors? The grant comes at a time when Exelixis’ stock is trading just below its 52‑week high (51.45 vs. 52.96), with a modest weekly gain of 0.68 %. The broader market sentiment—highlighted by a +40 social‑media score and 67 % buzz—suggests that investors are paying attention but remain cautious. Johnson’s option grant, coupled with a history of sizable option purchases in May 2025 and May 2026, reinforces the view that insiders expect continued growth, likely driven by the company’s pipeline developments and strategic partnerships. For shareholders, this alignment between insider and public interests can be a positive signal, potentially supporting a more favorable price trajectory.

Insider Trends at Exelixis In the past month, senior executives have been active: CEO Michael Morrissey sold a large block of common stock on May 15, while EVP Aftab Dana and CFO Christopher Senner also liquidated significant holdings. These sales may reflect portfolio rebalancing rather than a lack of confidence. In contrast, Johnson’s option purchase indicates a bet on future upside. The pattern of insiders selling while Johnson buys options suggests a diversification strategy—executives monetize existing equity, while directors lock in future gains.

David Johnson: A Profile of Cautious Commitment Johnson’s transaction history shows a consistent pattern of option activity: a 21,464‑share option purchase in May 2025 and the current 19,133‑share grant in May 2026. Unlike many insiders who sell shares, Johnson has refrained from liquidating stock, instead choosing to increase potential exposure through options. This strategy aligns with a long‑term view and a willingness to share risk with the company’s future valuation. His holdings through the Caligan Partners Master Fund also imply a sophisticated investment approach, leveraging institutional structures to manage tax and liquidity considerations.

Bottom Line for the Investor While insider sales may raise eyebrows, the net effect is neutral: executives are rebalancing portfolios, whereas Johnson’s option grant adds upside potential. Coupled with a healthy price‑earnings ratio of 16.58 and a solid market cap of $12.58 billion, Exelixis remains a compelling play for investors focused on biotech innovation. Monitoring subsequent vesting events and any future share purchases will provide further insight into whether insiders maintain their bullish stance or pivot in response to new clinical data or regulatory milestones.